Nearly all surveyed drug sellers (i.e. pharmacists) in the city of Daegu and the province of Gyeongbuk indicated a decrease, whether small or large, in outpatient prescriptions following the COVID-19 outbreak in South Korea in early 2020. Around 60 percent said they had seen decreases of between 11 percent and 40 percent. This trend matches that of most other regions in Korea. This decrease is attributed to fewer hospital visits in the midst of the COVID-19 crisis.
Changes in hospital outpatient prescriptions since COVID-19 outbreak in Daegu and Gyeongbuk in South Korea in 2020
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Starter Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$199 USD / Month *
Professional Account
Full access
Business Solutions including all features.
* Prices do not include sales tax.
Other statistics that may interest you Statistics on
About the industry
10
- Basic Statistic Top challenges for pharmaceutical companies during COVID-19 2020
- Premium Statistic Changes in outpatient prescriptions in Daejeon and Chungcheong South Korea 2020
- Premium Statistic Adjusted pharmaceutical sales forecast in South Korea 2020, by drug type
- Basic Statistic Launch disruption on global pharmaceutical market due to coronavirus 2020-2025
- Premium Statistic Impact of COVID-19 on OTC pharmacy sales South Korea 2020
- Premium Statistic Impact of COVID-19 on pharmacy operations in South Korea 2020
- Premium Statistic Impact of COVID-19 on revenue of hospitality and retail sector South Korea 2020
- Premium Statistic Changes in outpatient prescriptions in Gwangju and Jeolla South Korea 2020
- Premium Statistic Changes in outpatient prescriptions during COVID-19 in Seoul South Korea 2020
- Premium Statistic Changes in outpatient prescriptions in Gyeonggi/Incheon/Gangwon South Korea 2020
About the region
10
- Basic Statistic Moderna net income 2016-2023
- Basic Statistic R&D expenses of Moderna 2016-2023
- Basic Statistic Moderna Inc collaboration revenue by related party 2018-2023
- Basic Statistic R&D expenses of Moderna by type 2023
- Basic Statistic Moderna's revenue 2016-2023
- Basic Statistic Moderna total assets 2016-2023
- Premium Statistic Changes in outpatient prescriptions in Busan and Gyeongnam South Korea 2020
- Premium Statistic GSK's revenue by region 2013-2023
- Premium Statistic Biogen's top products based on revenue 2021-2023
- Premium Statistic Amgen's expenditure on research and development 2006-2023
Selected statistics
10
- Basic Statistic Sanofi's total assets 2007-2023
- Premium Statistic Merck & Co - expenditure on research and development 2006-2023
- Basic Statistic Merck & Co total assets 2009-2023
- Basic Statistic GSK's operating profit by division 2006-2021
- Premium Statistic Pfizer's revenues in the U.S. and abroad 2009-2023
- Premium Statistic AstraZeneca's expenditure on research and development 2006-2023
- Basic Statistic Merck & Co cash dividends declared 2006-2023
- Premium Statistic Johnson & Johnson's number of employees 2004-2023
- Premium Statistic Sales of Johnson & Johnson worldwide 2011-2023, by segment
- Premium Statistic Sales of Johnson & Johnson 2006-2023 by region
Other regions
10
- Basic Statistic YTD stock performance of biopharma companies working on COVID March 2020
- Premium Statistic Impact of COVID-19 on inbound tourist arrivals South Korea 2020
- Basic Statistic Pharmaceutical revenue as percent of health spending in African major countries 2014
- Premium Statistic Potential biosimilars savings in EU5 countries and the U.S. 2016-2020
- Premium Statistic Biotech industry growth rates in Australia compared to worldwide 2016
- Basic Statistic Pharma sales as share of health spending in Latin America by major country 2014
- Premium Statistic Pharmaceutical revenue as percent of health expenditure by Asian country 2014
- Premium Statistic Market size of biopharmaceuticals in China 2013-20225
- Premium Statistic Revenue value from biotechnology companies in Germany 2008-2022
- Basic Statistic Revenue of pharmaceutical markets in Central and Eastern Europe 2021-2022
Related statistics
10
- Premium Statistic Sales revenue Yuhan 2015-2023
- Premium Statistic Traditional medicine industry South Korea 2021, by sales revenue
- Premium Statistic Traditional medicine industry sales in South Korea 2021, by sector
- Premium Statistic Number of companies in biotech industry in South Korea 2022, by sector
- Premium Statistic R&D investment value in biotech industry in South Korea 2022, by sector
- Premium Statistic Impact of COVID-19 on revenue of airlines and duty-free South Korea 2020
- Premium Statistic New pharmaceutical drugs in R&D pipelines in South Korea 2014, by therapeutic area
- Premium Statistic Anti-diabetics estimated market size in South Korea 2014-2020
- Premium Statistic Cardiovascular disease drugs estimated market size in South Korea 2014-2020
- Premium Statistic Cholesterol drugs estimated market size in South Korea 2014-2020
Further related statistics
10
- Medicinal market growth worldwide including rebates 2009-2018
- Expenditure worldwide on diabetes by market 2013-2018
- Celgene's revenue and net income 2006-2018
- Key figures on established biotech centers worldwide 2012-2016
- M&A capacities - changes for the global pharma industry 2008-2015
- AstraZeneca's revenue from top product Pulmicort 2006-2023
- CVS Health's total assets 2005-2023
- Walgreens gross profit and net earnings in the U.S. 2005-2023
- Annual revenue of Sinopharm 2010-2022
- Number of employees at Sinopharm 2011-2022
Further Content: You might find this interesting as well
Statistics
- Medicinal market growth worldwide including rebates 2009-2018
- Expenditure worldwide on diabetes by market 2013-2018
- Celgene's revenue and net income 2006-2018
- Key figures on established biotech centers worldwide 2012-2016
- M&A capacities - changes for the global pharma industry 2008-2015
- AstraZeneca's revenue from top product Pulmicort 2006-2023
- CVS Health's total assets 2005-2023
- Walgreens gross profit and net earnings in the U.S. 2005-2023
- Annual revenue of Sinopharm 2010-2022
- Number of employees at Sinopharm 2011-2022
IQVIA. (March 31, 2020). Changes in hospital outpatient prescriptions since COVID-19 outbreak in Daegu and Gyeongbuk in South Korea in 2020 [Graph]. In Statista. Retrieved May 19, 2024, from https://www.statista.com/statistics/1120097/south-korea-changes-in-outpatient-prescriptions-in-daegu-and-gyeongbuk/
IQVIA. "Changes in hospital outpatient prescriptions since COVID-19 outbreak in Daegu and Gyeongbuk in South Korea in 2020." Chart. March 31, 2020. Statista. Accessed May 19, 2024. https://www.statista.com/statistics/1120097/south-korea-changes-in-outpatient-prescriptions-in-daegu-and-gyeongbuk/
IQVIA. (2020). Changes in hospital outpatient prescriptions since COVID-19 outbreak in Daegu and Gyeongbuk in South Korea in 2020. Statista. Statista Inc.. Accessed: May 19, 2024. https://www.statista.com/statistics/1120097/south-korea-changes-in-outpatient-prescriptions-in-daegu-and-gyeongbuk/
IQVIA. "Changes in Hospital Outpatient Prescriptions since Covid-19 Outbreak in Daegu and Gyeongbuk in South Korea in 2020." Statista, Statista Inc., 31 Mar 2020, https://www.statista.com/statistics/1120097/south-korea-changes-in-outpatient-prescriptions-in-daegu-and-gyeongbuk/
IQVIA, Changes in hospital outpatient prescriptions since COVID-19 outbreak in Daegu and Gyeongbuk in South Korea in 2020 Statista, https://www.statista.com/statistics/1120097/south-korea-changes-in-outpatient-prescriptions-in-daegu-and-gyeongbuk/ (last visited May 19, 2024)
Changes in hospital outpatient prescriptions since COVID-19 outbreak in Daegu and Gyeongbuk in South Korea in 2020 [Graph], IQVIA, March 31, 2020. [Online]. Available: https://www.statista.com/statistics/1120097/south-korea-changes-in-outpatient-prescriptions-in-daegu-and-gyeongbuk/